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Ocular inflammation has become a hot topic in ophthal-
mology, involving also several areas of medicine: internal
medicine, surgery, basic research, physiology, pharmacology,
microbiology, immunology, rheumatology, pharmacology, or
laboratory. There are many ocular inflammatory diseases in
different locations, including orbit, ocular adnexa, ocular
surface, conjunctiva, cornea, sclera, uvea, retinal vessels, and
optic nerve. Management of ocular inflammation presents
diagnostic and therapeutic challenges, ranging the etiology
and prognosis from benign, self-limited conditions to organ-
threatening disorders. Ocular inflammation is a component
of eye surgery, sometimes leading to its complications, such as
macular cystoid edema, and often being targeted by pharma-
cologic therapy or less invasive surgical procedures. Recently,
it has become clear that some assumed to be noninflam-
matory disorders, like age-related macular degeneration [1]
and macular edema secondary to diabetic retinopathy [2] or
retinal vein occlusion, are dependent on some inflammatory
mediators and thus should be treated, at least partially, as
inflammatory disorders.
Ocular inflammation is also often present in patients with
systemic inflammatory diseases, such as rheumatoid arthritis,
systemic lupus erythematosus, sarcoidosis, Wegener’s granu-
lomatosis, Sjo¨gren’s syndrome, polyarteritis nodosa, primary
antiphospholipid syndrome, Behc¸et’s syndrome, Kawasaki
disease, Cogan’s syndrome, and relapsing polychondritis. Eye
involvement in these conditions can not only be the first
symptom of the disease but also serve as a biomarker of the
severity of systemic inflammation. Furthermore, immuno-
logical therapy is being developed to assist the return of
healthy ocular immune responses and immune privilege in
the eye.
This special issue reports some pathogenetic, diagnostic,
and therapeutic aspects of ocular inflammation. We believe
that papers on markers or receptors which play an impor-
tant role in the pathogenesis of the ocular inflammation
deserve special attention. P. Pawlowski et al. showed that
macrophages and CD4 T lymphocytes are both engaged
in the active, severe, and long stage of inflammation in
the orbital tissue of patients with Graves’ orbitopathy (GO)
in “Markers of inflammation and fibrosis in the orbital
fat/connective tissue of patients with Graves’ orbitopathy:
clinical implications.” F. Ekici et al. reported that Eritoran
treatment resulted in less inflammatory damage in terms of
serum and retinochoroidal tissue parameters in “Effect of
the toll-like receptor 4 antagonist Eritoran on retinochoroidal
inflammatory damage in a rat model of endotoxin-induced
inflammation.”
M. Mesquida et al. showed that increased serum levels
of IFN-, TNF-, and IL-17A and hsCRP were associated with
active uveitis associated with Behc¸et’s disease (BD) andmight
serve as markers of disease activity in “Proinflammatory
cytokines and C-reactive protein in uveitis associated with
Behc¸et’s disease.” F. J. Ascaso et al. reviewed the role of
inflammation in the pathogenesis of macular edema (ME)
secondary to retinal vascular diseases. ME is a nonspecific
sign of numerous retinal vascular diseases.The role of inflam-
matory processes in the genesis of both diabetic macular
edema (DME) and ME secondary to retinal vein occlusion
(RVO) is discussed. The paper discusses the inflammatory
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mediators which are implicated, the effect of the different
intravitreal therapies, the recruitment of leukocytesmediated
by adhesion molecules, and the role of retinal Mu¨ller glial
(RMG) cells.
Finally, another report concludes that, in patients with
CMV in the HAART era, immune recovery may be associ-
ated with a greater number of inflammatory complications,
including ME and epiretinal membrane formation. Given
the range of ocular manifestations of HIV, routine ocular
examinations and screening for visual loss are recommended
in patientswithCD4 counts<50 cells/𝜇L in “Immune recovery
uveitis: pathogenesis, clinical symptoms, and treatment.”
We hope that the readers of this special issue will find
accurate data and updated reviews on the mechanisms of the
different spectrum of ocular inflammatory disorders. Also,
important questions may be resolved, such as inflammatory
responses inDME, inflammatory cells in orbital tissues ofGO






[1] M. Nita, A. Grzybowski, F. J. Ascaso, and V. Huerva, “Age-
related macular degeneration in the aspect of chronic low-
grade inflammation (pathophysiological paraInflammation),”
Mediators of Inflammation, vol. 2014, Article ID 930671, 10
pages, 2014.
[2] W. J. Lee, M. H. Kang, M. Seong, and H. Y. Cho, “Comparison
of aqueous concentrations of angiogenic and inflammatory
cytokines in diabeticmacular oedema andmacular oedema due
to branch retinal vein occlusion,” British Journal of Ophthalmol-
ogy, vol. 96, no. 11, pp. 1426–1430, 2012.
